The Future of Bespoke Medicines: 10 Key Insights from Julia Vitarello's Journey with Mila and a New Biotech Venture
By
<p>In 2018, Julia Vitarello's daughter Mila became the face of personalized medicine after receiving a drug specifically designed for her rare genetic mutation. Now, Vitarello is embarking on a new mission: launching a biotech company to scale the production of these individualized therapies. Her previous attempt, EveryONE Medicines, dissolved due to regulatory hurdles. Here are ten critical things you need to know about this evolving field and what Vitarello's next steps mean for the future of custom treatments.</p>
<h2 id="item1">1. The Mila Story: A Milestone in Personalized Medicine</h2>
<p>Mila Makovec was diagnosed with a rare, fatal neurological disorder caused by a unique mutation in the <em>MEF2C</em> gene. In a pioneering effort, researchers created a custom antisense oligonucleotide (ASO) tailored to her specific DNA error—a therapy dubbed <strong>milasen</strong>. This treatment stabilized her condition and sparked global interest in <em>n-of-1</em> therapies. Julia Vitarello, Mila's mother, became an advocate and entrepreneur, driven to make such bespoke medicines accessible to other families facing similar rare diseases. The success of milasen highlighted both the promise and the immense challenges of creating individualized drugs, from scientific complexity to regulatory and financial barriers.</p><figure style="margin:20px 0"><img src="https://www.statnews.com/wp-content/uploads/2026/04/AdobeStock_1843017107-1024x576.jpeg" alt="The Future of Bespoke Medicines: 10 Key Insights from Julia Vitarello's Journey with Mila and a New Biotech Venture" style="width:100%;height:auto;border-radius:8px" loading="lazy"><figcaption style="font-size:12px;color:#666;margin-top:5px">Source: www.statnews.com</figcaption></figure>
<h2 id="item2">2. EveryONE Medicines: A Vision That Fell Short</h2>
<p>After Mila's treatment, Vitarello co-founded <strong>EveryONE Medicines</strong> with the goal of industrializing ASO-based personalized therapies. The company aimed to develop a platform that could rapidly design and test these drugs for patients with ultra-rare mutations. However, the venture folded in 2023, primarily because <a href="#item3">FDA guidance</a> did not provide a clear enough path for investors. Vitarello stated that while the agency encouraged customized therapies, the lack of a formal approval framework made it impossible to secure sustainable funding. EveryONE's closure underscored the stark gap between scientific innovation and commercial viability in this niche.</p>
<h2 id="item3">3. The FDA's Mixed Message on Custom Therapies</h2>
<p>In 2022, the FDA released draft guidance on individualized antisense oligonucleotides, signaling support for n-of-1 trials. Yet, the guidance left critical questions unanswered—such as how to demonstrate safety and efficacy for a drug used in a single patient. Investor confidence waned because there was no defined path to eventual approval or reimbursement. Vitarello noted that the guidance “did not go far enough” to satisfy venture capital requirements. This regulatory ambiguity remains a major bottleneck for companies like EveryONE, which now <a href="#item4">Vitarello's new biotech</a> hopes to navigate differently.</p>
<h2 id="item4">4. A New Biotech on the Horizon: Learning from Failure</h2>
<p>Undeterred, Vitarello is launching a new company—unnamed as yet—focused on scaling bespoke medicine production while addressing the lessons of EveryONE. The new entity aims to work closely with regulators from the outset, building a transparent framework for development and reimbursement. Vitarello and her collaborators are currently seeking funders who understand the long-term horizon needed for these therapies. The new company will leverage advances in AI and genomics to reduce costs and turnaround times, potentially making n-of-1 treatments more viable for a broader range of patients.</p>
<h2 id="item5">5. Scaling Bespoke Medicine: The Scientific Hurdles</h2>
<p>Creating a drug for a single patient is incredibly resource intensive. Each ASO must be designed, synthesized, and tested for safety—a process costing hundreds of thousands of dollars. Scaling this requires standardized platforms that can automate design and leverage modular components. Vitarello's new venture will explore high-throughput screening and machine learning to predict which sequences are most effective. However, even with automation, the <em>in vivo</em> validation step remains costly and time-consuming. Overcoming these scientific hurdles is essential for moving from one-off miracles to routine treatment options.</p>
<h2 id="item6">6. The Regulatory Sandbox: Proposing a New Pathway</h2>
<p>One of EveryONE's proposed solutions was a <strong>regulatory sandbox</strong>—a framework allowing designated centers to produce and test individualized drugs under relaxed but monitored rules. This concept, similar to experiments in other industries, would enable data collection while protecting patients. The new biotech plans to advocate for such a pathway, possibly partnering with the FDA on a pilot program. Vitarello believes that a sandbox approach could reduce the burden of proof for each new therapy while generating real-world evidence to inform future approvals. Success here could transform the field.</p><figure style="margin:20px 0"><img src="https://www.statnews.com/wp-content/uploads/2026/04/AdobeStock_1843017107-645x645.jpeg" alt="The Future of Bespoke Medicines: 10 Key Insights from Julia Vitarello's Journey with Mila and a New Biotech Venture" style="width:100%;height:auto;border-radius:8px" loading="lazy"><figcaption style="font-size:12px;color:#666;margin-top:5px">Source: www.statnews.com</figcaption></figure>
<h2 id="item7">7. Patient Advocacy Driving Innovation</h2>
<p>Julia Vitarello is not a scientist or business executive by training—she is a mother turned advocate. Her personal experience with Mila gives her unique credibility and passion. She has testified before Congress, spoken at international conferences, and collaborated with researchers to push the boundaries of personalized medicine. This grassroots energy has been instrumental in drawing attention and funding to the cause. Vitarello’s new company will likely continue this advocacy, working with patient groups to ensure therapies are not just developed but also accessible and affordable.</p>
<h2 id="item8">8. Economic Viability: The Investor Equation</h2>
<p>Personalized therapies face a unique economic challenge: a one-time patient limits revenue potential. Venture capital traditionally seeks blockbuster returns from large markets. To attract investment, Vitarello's model must demonstrate <em>scale</em> through automation and shared infrastructure, treating each new mutation as a variation on a theme rather than a completely novel drug. Some experts suggest subscription models or government subsidies could work. The new biotech is exploring mixed funding, including non-dilutive grants and partnerships with disease foundations, to reduce reliance on traditional VCs.</p>
<h2 id="item9">9. Ethical Considerations: Who Gets a Custom Drug?</h2>
<p>With limited resources, difficult questions arise: Which patients have mutations that are “worthy” of a bespoke therapy? Should we prioritize children, rapidly progressing conditions, or those with larger potential populations? Vitarello has emphasized the need for equitable criteria, not just those based on a family's ability to pay. Her new company will incorporate an ethics board to ensure transparency in patient selection as they aim to treat a broad range of rare mutations—not just high-profile cases like Mila's.</p>
<h2 id="item10">10. The Road Ahead: Hope, Caution, and Collaboration</h2>
<p>The story of bespoke medicines is still in its infancy. Vitarello's persistence offers hope to countless families, but the road is fraught with scientific, regulatory, and financial obstacles. The success of her new venture depends on collaboration between scientists, regulators, investors, and patient communities. If she can build a sustainable model, it could pave the way for a new era of truly personalized care, where no mutation is too rare to treat. For now, the world watches—and waits for Julia Vitarello’s next bold move.</p>
<p><strong>Conclusion:</strong> Julia Vitarello’s journey from a mother seeking a cure for her daughter to a biotech entrepreneur illustrates both the extraordinary potential and formidable challenges of personalized medicine. While the failure of EveryONE Medicines highlighted regulatory and funding gaps, it also provided critical lessons. Her new venture, though still in formation, carries the hopes of many who believe that no patient should be left behind. The future of bespoke therapies will require bold innovation, systemic change, and unwavering advocacy—qualities Vitarello embodies. As she seeks new funders and collaborators, the field stands at a pivotal moment: can custom medicines become more than a rare exception? Only time and collective effort will tell.</p>
Tags: